Eli Lilly, the pharmaceutical titan currently riding a wave of success from its metabolic and weight-loss blockbusters, is looking to diversify its long-term portfolio. The company is reportedly in advanced negotiations to acquire Kelonia Therapeutics, a biotech firm specializing in genetic medicines, in a deal that could reach a valuation of $7 billion. The move signals a significant escalation in Lilly’s efforts to solidify its standing in the high-stakes oncology sector.
The acquisition centers on Kelonia’s proprietary technology for "in vivo" gene delivery, an approach that seeks to simplify and scale the administration of genetic therapies for blood cancers. Unlike traditional CAR-T therapies, which often require complex, multi-week manufacturing processes outside the patient’s body, Kelonia’s platform aims to modify cells directly within the patient. For Lilly, this represents more than just a new drug candidate; it is a strategic bet on the next generation of cancer treatment infrastructure.
This pivot comes at a time when the pharmaceutical industry is flush with capital from the GLP-1 boom but remains wary of future patent cliffs for existing blockbusters. By reinvesting the windfalls from drugs like Mounjaro and Zepbound into specialized oncology, Lilly is attempting to construct a more resilient, multi-pillar business model. If finalized, the deal would place the Indianapolis-based firm in direct competition with established leaders in the hematology space.
With reporting from *Exame Inovação*.
Source · Exame Inovação
